Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality
about
Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and the activity of semicarbazide-sensitive amine oxidaseEvaluation of circulating sRAGE in osteoporosis according to BMI, adipokines and fracture risk: a pilot observational study.Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAHsRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study.Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory diseaseThe AGE-RAGE Axis and Its Relationship to Markers of Cardiovascular Disease in Newly Diagnosed Diabetic Patients.Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up studyEmerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway.Non-professional marathon running: RAGE axis and ST2 family changes in relation to open-window effect, inflammation and renal functionIncreased AGE-RAGE ratio in idiopathic pulmonary fibrosis.Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease.Effect of diet-derived advanced glycation end products on inflammation.Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.A drop in the circulating concentrations of soluble receptor for advanced glycation end products is associated with seroconversion to autoantibody positivity but not with subsequent progression to clinical disease in children en route to type 1 diabDo Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort.Soluble and Endogenous Secretory Receptors for Advanced Glycation End Products in Threatened Preterm Labor and Preterm Premature Rupture of Fetal MembranesIs Elevated Levels of Serum Soluble Receptor for Advanced Glycation End Products Harmful in Cigarette Smokers?Association between advanced oxidation protein products and 5-year mortality risk among amazon riparian elderly population.Advanced glycation end products (AGEs) and its receptors in the pathogenesis of hyperthyroidism.Plasmatic Soluble Receptor for Advanced Glycation End Products as a New Oxidative Stress Biomarker in Patients with Prosthetic-Joint-Associated Infections?Long-term physical activity leads to a significant increase in serum sRAGE levels: a sign of decreased AGE-mediated inflammation due to physical activity?Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults.AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease.Carbonyl Stress and Microinflammation-Related Molecules as Potential Biomarkers in Schizophrenia.Glycaemic control in type 2 diabetic patients with chronic kidney disease: the impacts on enzymatic antioxidants and soluble RAGE.Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients.
P2860
Q33619918-87F8D959-A888-423E-A206-AC3381D17309Q33801160-7089B3DF-D553-45CB-8287-3558CE59327EQ34133874-AC878BE3-8010-4AEC-9450-00748DE5CE38Q35097016-97455E81-A397-4265-B820-EEFDA48927DFQ35991574-A6FA3E2A-F2B8-431C-8288-C34FE55DFEB7Q36081850-22ED984A-5F9D-4310-99ED-E0260CB12B75Q36091982-BB3CB73D-9C73-4736-B70A-AB53A87738C1Q36207823-832439EB-1675-48B2-9CD2-A02F6591C245Q37274188-8C54043D-D796-4ADC-90F6-25A6A9F1568CQ37396756-62DB6C82-7AAC-4B74-975A-1F1B7FFE4E8EQ38523267-3F5CFA96-35A7-44A8-BC28-95E219341F93Q38588208-568F775D-DFAF-48C4-B957-C3BF675D90D5Q38859313-3F09EAEF-1521-46BE-BA21-4903017F5A10Q39156521-E8087935-5E1F-4F7F-8BED-0FF2FB388916Q39158946-22AEE7F1-175D-4935-B6EF-C743D2395F99Q39313922-8930B15A-F372-4A3D-B312-37C1EC4AF389Q40298930-DD5D6C41-AB69-4288-AEAD-AEFA7C2A0743Q40977776-B7330822-354E-4DCA-9983-B8E0FC65CE5BQ41975172-23AF6078-0CBE-4612-B159-2A4D5F7B4FC6Q44532692-D7329DC5-9B1E-40B6-A7F1-6C7D8CDAD306Q46593328-3A3D8A54-7D21-43E0-866D-90CAC99C35DEQ48130190-B8D41B7C-6705-4CFC-936D-8A5AF400108AQ48170304-D5A80B29-59D2-4A9B-80B5-0DEC1D33FCB4Q51061874-0DF96F38-7C65-4E56-9976-E221995D03CFQ51747235-81E980AD-091F-493E-83D8-9D27FA6B383CQ54961738-067BC6CD-85C6-423C-80C3-C2A277E27FDAQ55043209-616923A7-260C-4AA0-AD6F-4BA721B4FB98Q55474587-9114FB26-77FA-48C4-BE16-503B5D689448
P2860
Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Low levels of serum soluble re ...... disease state: myth or reality
@ast
Low levels of serum soluble re ...... disease state: myth or reality
@en
Low levels of serum soluble re ...... disease state: myth or reality
@nl
type
label
Low levels of serum soluble re ...... disease state: myth or reality
@ast
Low levels of serum soluble re ...... disease state: myth or reality
@en
Low levels of serum soluble re ...... disease state: myth or reality
@nl
prefLabel
Low levels of serum soluble re ...... disease state: myth or reality
@ast
Low levels of serum soluble re ...... disease state: myth or reality
@en
Low levels of serum soluble re ...... disease state: myth or reality
@nl
P2860
P3181
P356
P1476
Low levels of serum soluble re ...... disease state: myth or reality
@en
P2093
Kailash Prasad
P2860
P3181
P356
10.1055/S-0033-1363423
P407
P577
2014-03-01T00:00:00Z